On January 5, Nuvalent insider Deborah Ann Miller sold 4,363 shares of company stock for a total transaction value of $424,607.16. Following the sale, Miller’s direct ownership declined by 8.89% to 44,723 shares valued at approximately $4.35 million. The transaction, disclosed in an SEC filing, marks the latest in a series of disposals by the senior vice president and underscores a notable shift in her equity stake within nine months of the company’s public listing.

Since mid-October, Deborah Ann Miller has executed six separate sales totaling 86,048 shares. Highlights include 24,200 shares sold on November 17 for $2.55 million and 21,800 shares on October 30 for $2.25 million. These dispositions have generated over $8.4 million in proceeds and represent a cumulative reduction of more than 40% in her original position. Such sustained divestment contrasts with typical lock-up expiration patterns and may signal rebalancing of personal holdings rather than corporate liquidity needs.

Nuvalent reported third-quarter EPS of ($1.70), missing consensus estimates by $0.31 and widening year-over-year losses from ($1.28). Research analysts now anticipate full-year EPS of approximately (3.86). Of the 16 firms covering the stock, 15 maintain a buy or overweight view, citing pipeline progress on RET and KRAS G12D inhibitors. Brokerages have adjusted targets following quarterly results, with at least four issuing upward revisions since mid-November, reflecting confidence in late-stage candidate data expected this year.

Institutional and hedge fund ownership stands at 97.26%, with recent activity led by GAMMA Investing LLC, which increased its stake by 47.6% to 335 shares during Q4. Aster Capital Management and Eastern Bank each initiated positions in Q3 valued at roughly $38,000 and $52,000 respectively, while Farther Finance Advisors grew its holdings by over 9,000% in Q2 to 1,213 shares. These movements indicate selective accumulation by specialty managers even as insiders reduce exposure.